Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on February 4, 2008

Cardiovascular Research, doi:10.1093/cvr/cvn025
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
78/3/590    most recent
cvn025v2
cvn025v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Wanrooij, E. J.A
Right arrow Articles by Kuiper, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Wanrooij, E. J.A
Right arrow Articles by Kuiper, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Vaccination against CD99 inhibits atherogenesis in LDL receptor-deficient mice

Eva J.A van Wanrooij*, Paula de Vos*, M. Gabriele Bixel{dagger}, Dietmar Vestweber{dagger}, Theo J.C. van Berkel* and Johan Kuiper*,#

* Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands
{dagger} Max-Planck-Institute of Molecular Biomedicine, Röntgenstr. 20, D48149, Münster, Germany

# To whom correspondence should be addressed: Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands; Tel: +31-(0)71-5274378; Fax: +31-(0)71-5276032; E-mail: j.kuiper{at}chem.leidenuniv.nl

Aims: Murine CD99 was recently found to be expressed on leukocytes and endothelial cells where it is concentrated at inter-endothelial contacts. Blockade of CD99 by specific antibodies inhibits leukocyte extravasation to inflamed sites in vivo. The aim of the present study is to show the role of CD99 in atherosclerosis using a CD99 vaccination protocol to block the function of CD99 during atherosclerosis.

Methods: We constructed a DNA vaccine against CD99 by cloning the extracellular domain of murine CD99 into pcDNA3. Vaccination was performed by oral administration of attenuated Salmonella typhimurium transformed with pcDNA3-CD99. This vaccination results in a CD99-specific, CD8-mediated cytotoxic response and subsequent reduction of CD99-expressing cells.

Results: We showed that CD99 is expressed on vascular endothelium overlying atherosclerotic plaques and found that CD99 expression is up-regulated during western-type diet feeding. CD99 vaccination induced the formation of CD8-positive T cells that were cytotoxic against cells transfected with pcDNA3-CD99. Activation of CD8+ T cells was demonstrated by a 30% increase in CD8+CD69+ double-positive T cells in spleen and mediastinal lymph nodes. Furthermore, lymphocytes isolated from CD99-vaccinated mice specifically lysed CD99-expressing cells. More importantly, vaccination against CD99 attenuated atherosclerotic lesion formation in the aortic valve leaflets by 38% and in the carotid artery by 69% as compared to mice that were vaccinated with a control vector. Furthermore, a lower number of cells were found in atherosclerotic lesions, implying that fewer leukocytes were recruited to these sites. These observations were accompanied by a decrease in CD99 expression on leukocytes.

Conclusion: We conclude that vaccination against CD99 decreases atherogenesis by the selective removal of CD99-expressing cells, which could reduce leukocyte recruitment into atherosclerotic lesions and attenuate atherogenesis.

KEYWORDS atherosclerosis; CD99; diapedesis; DNA vaccination


Time for primary review: 20


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
LupusHome page
J. Carvalho, R. Pereira, and Y. Shoenfeld
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, November 1, 2009; 18(13): 1209 - 1212.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.